Shareholders Equity: The sum of preferred and common equity items.
Swedish Orphan Biovitrum (BIOVF) had Shareholders Equity of $3.86B for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$2.89B |
|
$48.85M |
|
$638.95M |
|
$2.25B |
|
$2.80B |
|
$88.71M |
|
$-85.23M |
|
$3.47M |
|
$3.47M |
|
$48.65M |
|
$48.65M |
|
$48.65M |
|
$48.65M |
|
$88.71M |
|
$1.12B |
|
344.30M |
|
347.61M |
|
$0.14 |
|
$0.14 |
|
| Balance Sheet Financials | |
$1.48B |
|
$166.69M |
|
$5.41B |
|
$6.89B |
|
$1.64B |
|
$529.40M |
|
$1.39B |
|
$3.04B |
|
$3.86B |
|
$-1.16B |
|
|
Shareholders Equity |
$3.86B |
345.66M |
|
| Cash Flow Statement Financials | |
$875.34M |
|
$-438.85M |
|
$-441.81M |
|
$116.51M |
|
$106.39M |
|
$-10.12M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|